Rushbrook, Simon

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

The UK-PSCSC Consortium, Liu, J. Z., The International IBD Genetics Consortium, The International PSC Study Group, Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., Andreassen, O. A., et al. (2013) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 391

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

The UK-PSC Consortium, Ji, S.-G., The International IBD Genetics Consortium, The International PSC Study Group, Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., Kumasaka, N., et al. (2017) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 357

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

Cordell, H. J., Han, Y., Mells, G. F., Li, Y., Hirschfield, G. M., Greene, C. S., Xie, G., Juran, B. D., Zhu, D., Qian, D. C., et al. (2015) · Nature Communications

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 287

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis

Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 284

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

Cordell, H. J., Fryett, J. J., Ueno, K., Darlay, R., Aiba, Y., Hitomi, Y., Kawashima, M., Nishida, N., Khor, S.-S., Gervais, O., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 182

Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

Carbone, M., Nardi, A., Flack, S., Carpino, G., Varvaropoulou, N., Gavrila, C., Spicer, A., Badrock, J., Bernuzzi, F., Cardinale, V., et al. (2018) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 155

Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

Murillo Perez, C. F., Fisher, H., Hiu, S., Kareithi, D., Adekunle, F., Mayne, T., Malecha, E., Ness, E., van der Meer, A. J., Lammers, W. J., et al. (2022) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 107

X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

Asselta, R., Paraboschi, E. M., Gerussi, A., Cordell, H. J., Mells, G. F., Sandford, R. N., Jones, D. E., Nakamura, M., Ueno, K., Hitomi, Y., et al. (2021) · Gastroenterology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 55

Fine‐Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease

Blokker, B. A., Maijo, M., Echeandia, M., Galduroz, M., Patterson, A. M., Ten, A., Philo, M., Schungel, R., Gutierrez‐de Juan, V., Halilbasic, E., et al. (2019) · Hepatology

Sirtuins and Resveratrol in MedicineLiver physiology and pathology

Cited by 46

The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis

Barron‐Millar, B., Ogle, L., Mells, G., Flack, S., Badrock, J., Sandford, R., Kirby, J., Palmer, J., Jopson, L., Brain, J., et al. (2021) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 45

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis

Martinez-Gili, L., Pechlivanis, A., McDonald, J. A. K., Begum, S., Badrock, J., Dyson, J. K., Jones, R., Hirschfield, G., Ryder, S. D., Sandford, R., et al. (2023) · Gut Microbes

Liver Diseases and ImmunityGut microbiota and health

Cited by 32

The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study

Jones, D. E. J., Wetten, A., Barron-Millar, B., Ogle, L., Mells, G., Flack, S., Sandford, R., Kirby, J., Palmer, J., Brotherston, S., et al. (2022) · eBioMedicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 22